Prescription Description
| Prescription ID | TCMF29 |
| Pinyin Name | Fu Fang Zhen Zhu Kou Chuang Ke Li |
| Chinese Name | 复方珍珠口疮颗粒 |
| English Name | Fu Fang Zhen Zhu Kou Chuang Granules |
| Function Description | 心脾湿热证口疮, 症见口疮, 周围红肿, 中间凹陷, 表面黄白, 灼热疼痛, 口干口臭, 舌红 |
| Indications | Heat pattern, Aphtha |
| Disease ICD-11 Category |
SE72 [Heat pattern (TM1), 热证 (TM1)
]; DA01.10 [Oral aphthae or aphtha-like ulceration, 口腔阿弗他溃疡或阿弗他样溃疡 ]; |
| Human Tissues Associated with Indication | Skin, Lung |
| Reference | Chinese pharmacopoeia (2015) |
| Reference Book/link | ISBN 978-7-5067-7337-9 |
Prescription Components
| Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
|---|---|---|---|---|
| TCMH2605 | Margarita | 珍珠 | TCMH2605 | |
| TCMH2175 | Galla chinensis | 五倍子 | TCMH2175 | |
| TCMH211 | Atractylodes lancea | 苍术 | TCMH211 | ITSAN4439-14 |
| TCMH628 | Glycyrrhiza uralensis | 甘草 | TCMH628 | ITSAM892-14 |
Targeted Human Proteins by the Ingredients of Prescription
| Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
|---|---|---|---|---|
| TCMT100 | TTR | Transthyretin | Unclassified | P02766 |
| TCMT101 | PTPN1 | Protein-tyrosine phosphatase 1B | Hydrolase | P18031 |
| TCMT112 | ADORA3 | Adenosine A3 receptor | GPCR | P0DMS8 |
| TCMT127 | PARP1 | Poly [ADP-ribose] polymerase-1 | Transferase | P09874 |
| TCMT128 | TNKS2 | Tankyrase-2 | Transferase | Q9H2K2 |
| TCMT129 | TNKS | Tankyrase-1 | Transferase | O95271 |
| TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
| TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
| TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
| TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
| TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
| TCMT137 | CA9 | Carbonic anhydrase IX | Lyase | Q16790 |
| TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
| TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
| TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
| TCMT159 | TYR | Tyrosinase | Oxidoreductase | P14679 |
| TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
| TCMT17 | POLB | DNA polymerase beta | Transferase | P06746 |
| TCMT174 | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | Oxidoreductase | P28845 |
| TCMT190 | PTPN2 | T-cell protein-tyrosine phosphatase | Hydrolase | P17706 |
| TCMT209 | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | Oxidoreductase | P80365 |
| TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
| TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
| TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
| TCMT23 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Hydrolase | P05186 |
| TCMT231 | GBA2 | Beta-glucosidase | Hydrolase | Q9HCG7 |
| TCMT236 | ESR2 | Estrogen receptor beta | Nuclear receptor | Q92731 |
| TCMT249 | CDK6 | Cyclin-dependent kinase 6 | Kinase | Q00534 |
| TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
| TCMT260 | FLT3 | Tyrosine-protein kinase receptor FLT3 | Kinase | P36888 |
| TCMT261 | DAPK1 | Death-associated protein kinase 1 | Kinase | P53355 |
| TCMT280 | AKR1B10 | Aldo-keto reductase family 1 member B10 | Oxidoreductase | O60218 |
| TCMT296 | ADORA1 | Adenosine A1 receptor | GPCR | P30542 |
| TCMT297 | FABP4 | Fatty acid binding protein adipocyte | Unclassified | P15090 |
| TCMT298 | FABP3 | Fatty acid binding protein muscle | Hydrolase | P05413 |
| TCMT337 | XPO1 | Exportin-1 | Unclassified | O14980 |
| TCMT344 | AOX1 | Aldehyde oxidase | Oxidoreductase | Q06278 |
| TCMT46 | F3 | Coagulation factor III | Unclassified | P13726 |
| TCMT47 | BCL2 | Apoptosis regulator Bcl-2 | Ion channel | P10415 |
| TCMT506 | PTK2B | Protein tyrosine kinase 2 beta | Kinase | Q14289 |
| TCMT563 | CDC25B | Dual specificity phosphatase Cdc25B | Hydrolase | P30305 |
| TCMT591 | ESRRA | Estrogen-related receptor alpha | Nuclear receptor | P11474 |
| TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
| TCMT597 | SLC28A3 | Solute carrier family 28 member 3 | Transporter | Q9HAS3 |
| TCMT63 | PPARA | Peroxisome proliferator-activated receptor alpha | Nuclear receptor | Q07869 |
| TCMT636 | POLA1 | DNA polymerase alpha subunit | Transferase | P09884 |
| TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
| TCMT66 | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | Oxidoreductase | P37059 |
| TCMT709 | SLC28A2 | Sodium/nucleoside cotransporter 2 | Transporter | O43868 |
| TCMT710 | SLC28A1 | Sodium/nucleoside cotransporter 1 | Transporter | O00337 |
| TCMT734 | MMP12 | Matrix metalloproteinase 12 | Hydrolase | P39900 |
| TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
| TCMT808 | FABP5 | Fatty acid binding protein epidermal | Unclassified | Q01469 |
| TCMT809 | FABP2 | Fatty acid binding protein intestinal | Unclassified | P12104 |
| TCMT810 | TLR2 | Toll-like receptor 2 | Unclassified | O60603 |
| TCMT82 | ESR1 | Estrogen receptor alpha | Nuclear receptor | P03372 |
| TCMT822 | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Transferase | Q11130 |
| TCMT83 | CD38 | Lymphocyte differentiation antigen CD38 | Unclassified | P28907 |
| TCMT907 | FDPS | Farnesyl diphosphate synthase | Lyase | P14324 |
| TCMT910 | ESRRB | Estrogen-related receptor beta | Nuclear receptor | O95718 |
Targeted Pathogenic Microbes by the Ingredients of Prescription
| Target ID | Target Name |
|---|---|
| TCMT1170 | Enterobacter cloacae |
| TCMT1175 | Human immunodeficiency virus |
| TCMT1176 | Streptococcus pneumoniae |
| TCMT1178 | Actinomyces viscosus |
| TCMT1179 | Escherichia coli ATCC 8739 |
| TCMT1181 | Mycobacterium tuberculosis H37Ra |
| TCMT1186 | Plasmodium yoelii yoelii |
| TCMT1189 | Pseudomonas fluorescens |
| TCMT1209 | Staphylococcus haemolyticus |
| TCMT1210 | Streptococcus sobrinus |
| TCMT1211 | Fusobacterium nucleatum |
| TCMT1212 | Verticillium dahliae |
| TCMT1213 | Neisseria gonorrhoeae |
| TCMT1214 | Enterococcus faecium |
| TCMT1215 | Pseudomonas aeruginosa PAO1 |
| TCMT1218 | Staphylococcus aureus |
| TCMT1223 | Staphylococcus epidermidis |
| TCMT1224 | Proteus mirabilis |
| TCMT1226 | Klebsiella pneumoniae |
| TCMT1227 | Streptococcus |
| TCMT1229 | Enterococcus faecalis |
| TCMT1232 | Pseudomonas aeruginosa |
| TCMT1234 | Bacillus coagulans |
| TCMT1235 | Clostridium sporogenes |
| TCMT1236 | Mycobacterium bovis |
| TCMT1237 | Mycobacterium kansasii |
| TCMT1238 | Mycobacterium xenopi |
| TCMT1239 | Mycobacterium marinum |
| TCMT1243 | Aspergillus flavus |
| TCMT1246 | Escherichia coli |
| TCMT1248 | Hepatitis C virus |
| TCMT1249 | Dengue virus 2 |
| TCMT1251 | Candida albicans |
| TCMT1253 | Penicillium chrysogenum |
| TCMT1255 | Human immunodeficiency virus 1 |
| TCMT1284 | Penicillium expansum |
| TCMT1286 | Bacillus cereus |
| TCMT1294 | Human parainfluenza virus 3 |
| TCMT1321 | Staphylococcus hominis |
| TCMT1343 | Staphylococcus simulans |
| TCMT1344 | Staphylococcus sciuri |
| TCMT1346 | Helicobacter pylori |
| TCMT1349 | Helicobacter pylori SS1 |
| TCMT1361 | Neisseria meningitidis |
| TCMT1370 | Prevotella melaninogenica |
| TCMT1382 | Plasmodium falciparum (isolate K1 / Thailand) |
| TCMT1393 | Vibrio sp. |
| TCMT1412 | Salmonella typhimurium |
| TCMT1438 | Plasmodium falciparum |
| TCMT1439 | Mycobacterium smegmatis |
| TCMT1442 | Leishmania donovani |
| TCMT1443 | Leishmania amazonensis |
| TCMT1447 | Respiratory syncytial virus |
| TCMT1448 | Enterobacter aerogenes |
| TCMT1449 | Influenza A virus |
| TCMT1450 | Plasmodium falciparum 3D7 |
| TCMT1454 | Bacillus subtilis |
| TCMT1455 | Mycobacterium tuberculosis H37Rv |
| TCMT1457 | Leishmania major |
| TCMT1458 | Filobasidiella neoformans |
| TCMT1462 | Streptococcus mutans |
| TCMT1463 | Mycobacterium tuberculosis |
| TCMT1464 | Hepatitis B virus |
| TCMT1465 | Entamoeba histolytica |
Gene Ontology Associated to Targeted Human Proteins
| GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|---|
| [BP] GO:0008202 | steroid metabolic process | AKR1B1, AKR1B10, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, FDPS, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 10.0434 |
| [BP] GO:0006629 | lipid metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, FABP3, FABP4, FDPS, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA | 8.32481 |
| [BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 7.5221 |
| [BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 7.37812 |
| [BP] GO:0019748 | secondary metabolic process | AKR1B1, AKR1B10, BCL2, CYP1A1, CYP1A2, CYP1B1, TYR | 7.15645 |
| [BP] GO:0008152 | metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FLT3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 7.13444 |
| [BP] GO:0033993 | response to lipid | ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, ESR1, ESRRA, FABP3, FLT3, HSD11B2, HSD17B2, TYR | 6.97387 |
| [BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA4, CA7, CA9 | 6.39584 |
| [BP] GO:0044281 | small molecule metabolic process | AKR1B1, AKR1B10, AOX1, CA1, CA12, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FDPS, FUT7, GBA2, PPARA, TYR, XDH | 6.1028 |
| [BP] GO:0065008 | regulation of biological quality | ACHE, ADORA1, AKR1B1, BCL2, CA12, CA2, CA7, CDK6, CYP19A1, CYP1A1, CYP1B1, ESR1, F3, FABP3, FABP4, FLT3, HSD11B1, HSD11B2, HSD17B1, HSD17B2, POLA1, POLB, PPARA, TNKS, TNKS2, XDH | 5.53669 |
| [BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, ALPL, BCL2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, HSD11B2, HSD17B2, POLB, PPARA, TYR | 5.53669 |
| [BP] GO:0009725 | response to hormone | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, FLT3, HSD11B2, PPARA | 5.49818 |
| [BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD17B1, HSD17B2 | 5.2008 |
| [BP] GO:0042446 | hormone biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 5.2008 |
| [BP] GO:0048513 | animal organ development | ACHE, BCL2, CA2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, ESR1, ESRRA, ESRRB, FLT3, HSD11B1, HSD17B2, POLB, PPARA, TYR | 5.2008 |
| [BP] GO:0010033 | response to organic substance | AKR1B1, ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, FLT3, HSD11B2, HSD17B2, POLB, PPARA, TYR | 5.18618 |
| [BP] GO:0014070 | response to organic cyclic compound | ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FLT3, HSD11B2, TYR | 5.1142 |
| [BP] GO:0006694 | steroid biosynthetic process | AKR1B1, CYP19A1, FDPS, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 4.85941 |
| [BP] GO:0010817 | regulation of hormone levels | ACHE, ADORA1, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 4.79415 |
| [BP] GO:0032847 | regulation of cellular pH reduction | BCL2, CA2, CA7 | 4.46412 |
| [BP] GO:0044237 | cellular metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FABP3, FABP4, FDPS, FLT3, FUT7, GBA2, HSD17B1, HSD17B2, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 4.19697 |
| [BP] GO:0055114 | oxidation-reduction process | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 4.19697 |
| [BP] GO:0016042 | lipid catabolic process | ADORA1, AKR1B10, CYP19A1, CYP1A2, CYP1B1, FABP3, FABP4, GBA2 | 3.90641 |
| [BP] GO:0042221 | response to chemical | AKR1B1, ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, FLT3, HSD11B2, HSD17B2, POLB, PPARA, TYR | 3.82871 |
| [BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1, HSD17B2 | 3.82468 |
| [BP] GO:0009719 | response to endogenous stimulus | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, FLT3, HSD11B2, PPARA | 3.80172 |
| [BP] GO:0044238 | primary metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FLT3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 3.7484 |
| [BP] GO:1901615 | organic hydroxy compound metabolic process | AKR1B1, AKR1B10, BCL2, CYP19A1, CYP1A1, CYP1B1, FDPS, GBA2, TYR | 3.66409 |
| [BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA4, CA7, CA9, FABP3, PPARA | 3.63813 |
| [BP] GO:0008610 | lipid biosynthetic process | ACHE, AKR1B1, CSNK2A1, CYP19A1, CYP1A1, FDPS, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.62085 |
| [BP] GO:0048856 | anatomical structure development | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, FLT3, GBA2, HSD11B1, HSD17B2, POLB, PPARA, TYR | 3.41568 |
| [BP] GO:0032502 | developmental process | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, FABP4, FLT3, FUT7, GBA2, HSD11B1, HSD17B2, POLB, PPARA, TNKS2, TYR | 3.36959 |
| [BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.2186 |
| [BP] GO:0044255 | cellular lipid metabolic process | ACHE, AKR1B10, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FDPS, FUT7, GBA2, PPARA | 3.14672 |
| [BP] GO:0071704 | organic substance metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FLT3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 3.14672 |
| [BP] GO:0042127 | regulation of cell proliferation | ADORA1, ADORA3, AKR1B1, BCL2, CDC25B, CDK6, CSNK2A1, CYP1B1, ESR1, ESRRA, F3, FABP3, FLT3, MMP12, XDH | 2.93076 |
| [BP] GO:0010647 | positive regulation of cell communication | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, FLT3, MMP12, PTPN1, TNKS, TNKS2, XDH | 2.91635 |
| [BP] GO:0006703 | estrogen biosynthetic process | CYP19A1, HSD17B1, HSD17B2 | 2.91635 |
| [BP] GO:0023056 | positive regulation of signaling | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, FLT3, MMP12, PTPN1, TNKS, TNKS2, XDH | 2.9034 |
| [BP] GO:0006820 | anion transport | CA1, CA12, CA14, CA2, CA4, CA7, CA9, FABP3, PPARA | 2.82469 |
| [BP] GO:0006721 | terpenoid metabolic process | AKR1B10, CYP1A1, CYP1A2, CYP1B1, FDPS | 2.76914 |
| [BP] GO:0009115 | None | AOX1, XDH | 2.76914 |
| [BP] GO:0016137 | None | AKR1B1, AKR1B10, GBA2 | 2.52282 |
| [BP] GO:0006720 | isoprenoid metabolic process | AKR1B10, CYP1A1, CYP1A2, CYP1B1, FDPS | 2.46654 |
| [BP] GO:0009056 | catabolic process | ACHE, ADORA1, AKR1B10, AOX1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FUT7, GBA2, MMP12, XDH | 2.41791 |
| [BP] GO:0043401 | steroid hormone mediated signaling pathway | ESR1, ESR2, ESRRA, ESRRB, PPARA | 2.39543 |
| [BP] GO:0050896 | response to stimulus | ACHE, ADORA1, ADORA3, AKR1B1, ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, F3, FABP3, FABP4, FLT3, HSD11B2, HSD17B2, MMP12, POLA1, POLB, PPARA, PTPN1, TYR | 2.34451 |
| [BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 2.34451 |
| [BP] GO:0046110 | None | AOX1, XDH | 2.34451 |
| [BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.34451 |
| [BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.23508 |
| [BP] GO:1901360 | None | ACHE, AKR1B1, AKR1B10, AOX1, BCL2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FDPS, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, POLA1, POLB, PPARA, TYR, XDH | 2.2121 |
| [BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1 | 2.1884 |
| [BP] GO:0070213 | None | TNKS, TNKS2 | 2.08553 |
| [BP] GO:0006145 | None | AOX1, XDH | 2.08553 |
| [BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.08553 |
| [BP] GO:0006367 | transcription initiation from RNA polymerase II promoter | ESR1, ESR2, ESRRA, ESRRB, PPARA | 2.02977 |
| [BP] GO:0022900 | electron transport chain | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.00884 |
| [CC] GO:0044432 | endoplasmic reticulum part | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FLT3, GBA2, HSD11B1, HSD11B2, HSD17B2, PTPN1 | 1.49857 |
| [CC] GO:0043227 | membrane-bounded organelle | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA2, CA4, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FLT3, FUT7, GBA2, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 1.49136 |
| [CC] GO:0044444 | cytoplasmic part | ACHE, ADORA1, AKR1B1, AKR1B10, AOX1, BCL2, CA1, CA2, CA4, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, FABP3, FABP4, FDPS, FLT3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, POLA1, PTPN1, TNKS, TNKS2, TYR, XDH | 1.49136 |
| [CC] GO:0005789 | endoplasmic reticulum membrane | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GBA2, HSD11B1, HSD11B2, HSD17B2 | 1.3474 |
| [CC] GO:0043231 | intracellular membrane-bounded organelle | ACHE, ADORA1, AKR1B1, AKR1B10, BCL2, CA4, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FABP4, FDPS, FLT3, FUT7, GBA2, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 1.01554 |
| [MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 10.4296 |
| [MF] GO:0046914 | transition metal ion binding | AOX1, CA1, CA12, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, MMP12, PPARA, PTPN1, TNKS, TYR, XDH | 10.1598 |
| [MF] GO:0003824 | catalytic activity | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, F3, FDPS, FLT3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP12, POLA1, POLB, PTPN1, TNKS, TNKS2, TYR, XDH | 7.71035 |
| [MF] GO:0016835 | carbon-oxygen lyase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9, POLB | 7.5287 |
| [MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 7.00295 |
| [MF] GO:0043167 | ion binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FLT3, HSD17B1, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 5.91727 |
| [MF] GO:0016614 | oxidoreductase activity, acting on CH-OH group of donors | AKR1B1, AKR1B10, AOX1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, XDH | 5.85662 |
| [MF] GO:0008270 | zinc ion binding | CA1, CA12, CA2, CA4, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, MMP12, PPARA, PTPN1, TNKS | 5.43786 |
| [MF] GO:0016491 | oxidoreductase activity | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 5.10992 |
| [MF] GO:0016829 | lyase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9, POLB | 5.04617 |
| [MF] GO:0043169 | cation binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FDPS, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 5.03685 |
| [MF] GO:0046872 | metal ion binding | ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FDPS, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 4.56235 |
| [MF] GO:0005496 | steroid binding | ESR1, ESR2, ESRRA, ESRRB, HSD11B2, HSD17B1 | 4.45632 |
| [MF] GO:0098531 | transcription factor activity, direct ligand regulated sequence-specific DNA binding | ESR1, ESR2, ESRRA, ESRRB, PPARA | 4.19697 |
| [MF] GO:0004879 | nuclear receptor activity | ESR1, ESR2, ESRRA, ESRRB, PPARA | 4.19697 |
| [MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.87093 |
| [MF] GO:0003707 | steroid hormone receptor activity | ESR1, ESR2, ESRRA, ESRRB, PPARA | 3.82871 |
| [MF] GO:0016616 | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | AKR1B1, AKR1B10, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.7484 |
| [MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.71743 |
| [MF] GO:0033764 | steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.66409 |
| [MF] GO:0016229 | steroid dehydrogenase activity | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.56347 |
| [MF] GO:0048037 | cofactor binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B2, HSD17B1, POLA1, XDH | 3.1676 |
| [MF] GO:0005506 | iron ion binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, XDH | 3.10444 |
| [MF] GO:0004497 | monooxygenase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 2.95233 |
| [MF] GO:0008289 | lipid binding | ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, HSD11B2, HSD17B1, PPARA | 2.91635 |
| [MF] GO:0016903 | None | AKR1B1, AKR1B10, AOX1, XDH | 2.91635 |
| [MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 2.89004 |
| [MF] GO:0038052 | RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | ESR1, ESR2 | 2.76914 |
| [MF] GO:0003845 | None | HSD11B1, HSD11B2 | 2.76914 |
| [MF] GO:0009055 | electron transfer activity | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.76463 |
| [MF] GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 2.08553 |
| [MF] GO:0034056 | estrogen response element binding | ESR1, ESR2 | 2.08553 |
KEGG Pathways Associated to Targeted Human Proteins
| KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|
| Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA2, CA4, CA7, CA9, CA14 | 12.3773 |
| Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD11B1, HSD11B2, HSD17B1, HSD17B2, CYP1A2, CYP1A1, CYP1B1, CYP19A1 | 10.4238 |
| Metabolic pathways_Homo sapiens_hsa01100 | FDPS, AKR1B1, TYR, GBA2, CYP19A1, HSD11B1, POLA1, FUT7, AKR1B10, HSD17B1, HSD17B2, CYP1A2, CYP1A1, AOX1, ALPL, XDH | 6.6017 |
| Ovarian steroidogenesis_Homo sapiens_hsa04913 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1 | 5.5812 |
| Tryptophan metabolism_Homo sapiens_hsa00380 | CYP1A2, CYP1A1, AOX1, CYP1B1 | 4.3584 |
| Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.3857 |
| Chemical carcinogenesis_Homo sapiens_hsa05204 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.2533 |
| Retinol metabolism_Homo sapiens_hsa00830 | CYP1A2, CYP1A1, AOX1 | 2.2839 |
| PPAR signaling pathway_Homo sapiens_hsa03320 | FABP3, FABP4, PPARA | 2.2534 |
| Sphingolipid signaling pathway_Homo sapiens_hsa04071 | ADORA3, BCL2, ADORA1 | 1.706 |
| MicroRNAs in cancer_Homo sapiens_hsa05206 | CDK6, BCL2, CYP1B1, CDC25B | 1.5355 |
| Tyrosine metabolism_Homo sapiens_hsa00350 | AOX1, TYR | 1.6955 |
| Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | FABP4, ADORA1 | 1.3711 |
| Galactose metabolism_Homo sapiens_hsa00052 | AKR1B10, AKR1B1 | 1.7275 |
| Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 1.9208 |
| Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B10, AKR1B1 | 1.3508 |
| Prolactin signaling pathway_Homo sapiens_hsa04917 | ESR1, ESR2 | 1.2281 |
| Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B10, AKR1B1 | 1.6955 |
| Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B10, AKR1B1 | 1.7066 |
| Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP1A2, AOX1 | 1.2422 |
| Adherens junction_Homo sapiens_hsa04520 | PTPN1, CSNK2A1 | 1.2256 |
| AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | BCL2, F3 | 1.0598 |
| Small cell lung cancer_Homo sapiens_hsa05222 | CDK6, BCL2 | 1.1396 |
| Estrogen signaling pathway_Homo sapiens_hsa04915 | ESR1, ESR2 | 1.0598 |
| Cholinergic synapse_Homo sapiens_hsa04725 | ACHE, BCL2 | 1.0147 |
| NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1, BCL2 | 1.0933 |
| Insulin resistance_Homo sapiens_hsa04931 | PTPN1, PPARA | 1.0147 |
| Measles_Homo sapiens_hsa05162 | CDK6, CSNK2A1 | 0.8959 |
| Hepatitis B_Homo sapiens_hsa05161 | CDK6, BCL2 | 0.8668 |
| Cell cycle_Homo sapiens_hsa04110 | CDK6, CDC25B | 0.9551 |
| Jak-STAT signaling pathway_Homo sapiens_hsa04630 | BCL2, AOX1 | 0.83 |
| cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | ADORA3, ADORA1 | 0.806 |
| Pathways in cancer_Homo sapiens_hsa05200 | CDK6, FLT3, BCL2 | 0.806 |
| Purine metabolism_Homo sapiens_hsa00230 | POLA1, XDH | 0.806 |
| Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1, BCL2 | 0.7662 |
| cAMP signaling pathway_Homo sapiens_hsa04024 | ADORA1, PPARA | 0.7662 |
| Viral carcinogenesis_Homo sapiens_hsa05203 | POLB, CDK6 | 0.7662 |
| HTLV-I infection_Homo sapiens_hsa05166 | POLB, FDPS | 0.6568 |
| Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | ADORA3, ADORA1 | 0.6364 |
| PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | CDK6, BCL2 | 0.595 |
| Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | CDC25B | 0.5797 |
| Apoptosis_Homo sapiens_hsa04210 | BCL2 | 0.5047 |
| Prostate cancer_Homo sapiens_hsa05215 | BCL2 | 0.595 |
| Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | FLT3 | 0.3382 |
| Glioma_Homo sapiens_hsa05214 | CDK6 | 0.6364 |
| MAPK signaling pathway_Homo sapiens_hsa04010 | CDC25B | 0.3463 |
| Insulin signaling pathway_Homo sapiens_hsa04910 | PTPN1 | 0.5047 |
| Melanogenesis_Homo sapiens_hsa04916 | TYR | 0.5787 |
| Protein processing in endoplasmic reticulum_Homo sapiens_hsa04141 | BCL2 | 0.4554 |
| Hepatitis C_Homo sapiens_hsa05160 | PPARA | 0.505 |
| Hematopoietic cell lineage_Homo sapiens_hsa04640 | FLT3 | 0.595 |
| Chronic myeloid leukemia_Homo sapiens_hsa05220 | CDK6 | 0.6323 |
| Tight junction_Homo sapiens_hsa04530 | CSNK2A1 | 0.5047 |
| Pancreatic cancer_Homo sapiens_hsa05212 | CDK6 | 0.6364 |
| Central carbon metabolism in cancer_Homo sapiens_hsa05230 | FLT3 | 0.6364 |
| Glucagon signaling pathway_Homo sapiens_hsa04922 | PPARA | 0.5787 |
| Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | ESRRB | 0.5047 |
| Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | ESR1 | 0.5399 |
| HIF-1 signaling pathway_Homo sapiens_hsa04066 | BCL2 | 0.5764 |
| Colorectal cancer_Homo sapiens_hsa05210 | BCL2 | 0.6364 |
| Neurotrophin signaling pathway_Homo sapiens_hsa04722 | BCL2 | 0.5385 |
| Influenza A_Homo sapiens_hsa05164 | FDPS | 0.4475 |
| Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | PPARA | 0.4915 |
| Morphine addiction_Homo sapiens_hsa05032 | ADORA1 | 0.5919 |
| Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | BCL2 | 0.4942 |
| Wnt signaling pathway_Homo sapiens_hsa04310 | CSNK2A1 | 0.5047 |
| Focal adhesion_Homo sapiens_hsa04510 | BCL2 | 0.4177 |
| Proteoglycans in cancer_Homo sapiens_hsa05205 | ESR1 | 0.4177 |
| Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | FLT3 | 0.4465 |
| Tuberculosis_Homo sapiens_hsa05152 | BCL2 | 0.4465 |
| Melanoma_Homo sapiens_hsa05218 | CDK6 | 0.6364 |
| Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1 | 0.4412 |
| Non-small cell lung cancer_Homo sapiens_hsa05223 | CDK6 | 0.656 |
| Toxoplasmosis_Homo sapiens_hsa05145 | BCL2 | 0.5399 |
| Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.5824 |
| Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.595 |
| Acute myeloid leukemia_Homo sapiens_hsa05221 | FLT3 | 0.656 |
| Gastric acid secretion_Homo sapiens_hsa04971 | CA2 | 0.6323 |
| Renin secretion_Homo sapiens_hsa04924 | ADORA1 | 0.6364 |
| Pancreatic secretion_Homo sapiens_hsa04972 | CA2 | 0.5824 |
| Adipocytokine signaling pathway_Homo sapiens_hsa04920 | PPARA | 0.6364 |
| Pyrimidine metabolism_Homo sapiens_hsa00240 | POLA1 | 0.5743 |
| Peroxisome_Homo sapiens_hsa04146 | XDH | 0.5989 |
| Complement and coagulation cascades_Homo sapiens_hsa04610 | F3 | 0.6124 |
| p53 signaling pathway_Homo sapiens_hsa04115 | CDK6 | 0.6364 |
| Bile secretion_Homo sapiens_hsa04976 | CA2 | 0.6364 |
| Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | ESR1 | 0.6957 |
| Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | BCL2 | 0.6782 |
| Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | AOX1 | 0.6953 |
| Drug metabolism - other enzymes_Homo sapiens_hsa00983 | XDH | 0.6957 |
| Sphingolipid metabolism_Homo sapiens_hsa00600 | GBA2 | 0.6957 |
| Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | HSD11B2 | 0.7476 |
| Caffeine metabolism_Homo sapiens_hsa00232 | CYP1A2, XDH | 3.1741 |
| Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2 | 0.806 |
| DNA replication_Homo sapiens_hsa03030 | POLA1 | 0.7662 |
| Other types of O-glycan biosynthesis_Homo sapiens_hsa00514 | FUT7 | 0.7878 |
| Base excision repair_Homo sapiens_hsa03410 | POLB | 0.7716 |
| Glycosphingolipid biosynthesis - lacto and neolacto series_Homo sapiens_hsa00601 | FUT7 | 0.806 |
| Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | AOX1 | 0.806 |
| Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 0.806 |
| Terpenoid backbone biosynthesis_Homo sapiens_hsa00900 | FDPS | 0.833 |
| Other glycan degradation_Homo sapiens_hsa00511 | GBA2 | 0.8928 |
| Folate biosynthesis_Homo sapiens_hsa00790 | ALPL | 0.9586 |
| Vitamin B6 metabolism_Homo sapiens_hsa00750 | AOX1 | 1.2073 |
Target Exprsssion in Healthy Human Tissues (protein & mRNA level)
Protein expression data was from the "Human Proteome Map" datasetmRNA expression data was from the "GTEx" dataset
Average Target Expression (Fold Change) in Multiple Disease Conditions
Fold Change with Corresponding Normal SamplesClick each cell within the heatmap to access gene expression of individual patient samples